Paeonol ameliorates murine alcohol liver disease via mycobiota‐mediated Dectin‐1/IL‐1β signaling pathway. Issue 1 (4th March 2020)

• Record Type: Journal Article
• Authors: Wu, Jiadi; Wu, Daqiang; Ma, Kelong; Wang, Tianming; Shi, Gaoxiang; Shao, Jing; Wang, Changzhong; Yan, Guiming
• Is Part Of: Journal of leukocyte biology. Volume 108:Issue 1(2020)
• Page Start: 199
• Page End: 214
• Publication Date: 2020-03-04
• Subjects: alcohol liver disease -- paeonol -- dysbiosis -- intestinal barrier function -- Kupffer cells -- Candida albicans; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1002/JLB.3MA0120-325RR
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract: Alcoholic liver disease (ALD) is caused by long‐term consumption of alcohol and has become an important social and medical problem. Intestinal fungal flora (mycobiota) play an important role in ALD, so we used the mycobiota as an entry point to explore the mechanism of action of Paeonol against ALD. Here, we found that Paeonol is effective against ALD inflammatory lesions and relieves liver fat lesions. Furthermore, we found that after the treatment of Paeonol, the fungal dysbiosis is improved, and the fungal abundance is reduced, and the translocation of β‐glucan to the liver and its mediated Dectin‐1/IL‐1β signaling pathway is blocked. Our study shows that paeonol ameliorated acute ALD‐related inflammatory injury to the liver by alleviating intestinal fungal dysbiosis and inhibiting the mycobiota‐mediated Dectin‐1/IL‐1β signaling pathway. Abstract : Paeonol ameliorates alcoholic liver disease‐related inflammatory injury by alleviating intestinal fungal dysbiosis and inhibiting the mycobiota‐mediated Dectin‐1/IL‐1β signaling pathway.